ProPacífico, with strategic support from BMS, uses Arkangel AI to measure adherence across a complete cohort, detect early-detection deviations, and prioritize high-risk patients.
Operated by
ProPacífico
Scale
Complete pilot cohort
Technology
Arkangel AI
Strategic ally
Coverage
Valle · Cauca · Nariño
6,530
patient charts processed end to end
436
High-risk
38%
No endoscopy
17.1%
Actionable finding
Real-time findings
High risk without endoscopy
patient #4823
Family history undocumented
#4824
Clinical pathway complete
#4825
436
patients flagged as high risk
38%
high-risk patients without endoscopy on file
17.1%
of audited patients had an actionable finding
100%
coverage over records processed in the pilot.
38%
of high-risk patients without an ordered or completed endoscopy.
17.1%
of reviewed patients had actionable findings.
32%
of gastric cancer patients globally receive NCCN-adherent treatment.
In that cohort, Arkangel AI automatically classified 436 patients (7%) as high risk; finding them previously required manual chart-by-chart review.
Globally, it is the 5th most common cancer and the 5th leading cause of cancer death, with nearly one million new cases and 659,853 deaths in 2022. In Colombia, 8,938 new cases are reported each year (Global Cancer Observatory).
ProPacífico has been supporting a collaborative effort in Colombia’s Southwest (Valle, Cauca, and Nariño) with support from Bristol Myers Squibb (BMS) as a strategic ally. The region already has a clinical-administrative pathway for gastric cancer and a medical education strategy, but adherence in clinical practice remains a challenge.
Early detection is decisive: when cancer is identified in initial stages, the probability of survival increases significantly.
8,938
New cases per year in Colombia
Globocan 2022, Colombia fact sheet.
659,853
Global deaths in 2022
Gastric cancer is the 5th global cause of cancer death.
Manual audits are partial · Guidelines keep moving · Deviations have consequences.
Manual audits are partial
Teams can review samples, but most charts remain invisible until the next reporting cycle.
Guidelines keep moving
Medical evidence changes faster than operational audit capacity can scale.
Deviations have consequences
A missing endoscopy for a high-risk patient is not a data gap. It is a delayed opportunity.
Arkangel AI identifies deviations in early detection, diagnosis, staging, treatment, and follow-up while keeping clinicians in control.
Ingest every chart
Structured and unstructured clinical evidence enters the audit workflow.
Compare to pathway
Arkangel AI evaluates each patient against ProPacífico’s pathway and Ministry guidance.
Prioritize action
Teams receive patient-level findings, missing variables, and pathway deviations.
Important. The solution does not replace medical judgment or automate clinical decisions. It works as an audit, detection, and clinical decision-support system. ProPacífico’s designed clinical pathway is the reference Pandora uses to identify when it is not being followed.
In that cohort, Arkangel AI automatically classified 436 patients (7%) as high risk; finding them previously required manual chart-by-chart review.
436
patients flagged as high risk · 7% of the audited cohort
high-risk patients without endoscopy on file
38%
of audited patients had an actionable finding
17.1%
of gastric cancer patients globally receive NCCN-adherent treatment.
32%
6,530
patient charts processed end to end
The real size of the audited cohort
38%
high-risk patients without endoscopy on file
The most consequential detection gap
17.1%
of audited patients had an actionable finding
A concrete review queue for clinical teams
100%
100% pathway coverage
Not a quarterly sample. Every processed chart is checked against the pathway and Ministry of Health guidance.
Arkangel AI showed that general clinical documentation was strong, while risk variables for gastric cancer were frequently missing.
99%+
Strong general documentation signals.
~32%
Critical risk variables often missing.
Patient-level dashboards and reports expose deviations when they happen.
×See how Arkangel AI turns every chart into an evidence-checked pathway review, with clinicians in control.
High-risk patients without protocol-required endoscopy are visible and actionable.
Documentation gaps become targeted education and quality-improvement work.